ArticleWorld journal of surgery2026
Association of Pre-Transplant Tyrosine Kinase Inhibitor Therapy With Tumor Response and Survival in Hepatocellular Carcinoma: A 10-Year Retrospective Cohort Study of 427 Patients.
Article in World journal of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07418138 (Efficacy and Safety of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with hepatocellular carcinoma (HCC) awaiting liver transplantation remain at risk of tumor progression during the waiting period, highlighting the need for effective bridging or downstaging strategies. Although tyrosine kinase inhibitors (TKIs) are widely used in advanced HCC, their role in the pre-transplant setting remains unclear. This study evaluated the association of pre-transplant TKI therapy with survival, tumor response, and safety in HCC patients undergoing liver transplantation.
methodsWe retrospectively analyzed 427 patients with HCC who underwent orthotopic liver transplantation (OLT) between January 2015 and December 2024. Two separate propensity score matching (PSM) analyses were performed to compare outcomes between patients with and without pre-transplant TKI therapy, and to evaluate the additional association of TKIs among patients receiving transarterial chemoembolization (TACE). Primary outcomes were overall survival (OS) and recurrence-free survival (RFS). Tumor response and safety were also assessed.
resultsAfter PSM, 160 matched patients were included in the primary analysis. Pre-transplant TKI therapy was associated with longer RFS (log-rank p < 0.05) and lower recurrence rates (p = 0.007), greater pathological tumor necrosis (p < 0.001), and higher radiological response rates (all p < 0.05). Higher 5- and 10-year OS and RFS rates were also observed in the TKIs group (all p < 0.05). On multivariable analysis, pre-transplant TKI therapy remained associated with lower recurrence risk but not OS. Exploratory subgroup analyses suggested that these associations were more evident in patients beyond conventional transplant criteria. Among 120 matched patients receiving TACE, combined TACE and TKI therapy was associated with better survival and tumor response (all p < 0.05). Palmar-plantar erythrodysesthesia occurred more frequently in the TKIs group (p = 0.035), whereas major perioperative complications were comparable between groups, although ICU stay was slightly longer in the TKIs group (p = 0.034).
conclusionsPre-transplant TKI therapy, particularly when combined with TACE, was associated with better tumor response and favorable long-term outcomes without an apparent increase in major perioperative risk. These associations appeared more evident in patients beyond conventional transplant criteria. Prospective studies are needed to further validate these findings.
trial registrationThis study was registered with ClinicalTrials.gov (registry number NCT07418138).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.